NextCure Q2 net loss narrows on lower expenses

NextCure

06/08/2026 21:16

Overview
U.S. cancer drug developer's Q2 net loss narrowed yr/yr on lower R&D and admin costs
Company announced proposed merger with Avere Therapeutics, expected to close in H2 2026
NextCure advanced restructuring to cut costs and preserve capital ahead of merger

Outlook
NextCure expects merger with Avere Therapeutics to close in the second half of 2026
Company is preserving capital and reducing expenses in support of merger completion
NextCure is seeking to preserve value in legacy clinical and pre-clinical assets

Result Drivers
LOWER R&D SPENDING - Q2 research and development expenses fell due to absence of prior-year license fees
RESTRUCTURING COSTS - Asset impairment charges tied to restructuring and facility reductions impacted results
LOWER ADMINISTRATIVE COSTS - General and administrative expenses declined due to lower personnel-related costs

Company press release: ID:nGNX936zBt

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$14.89 mln
 
Q2 Income from Operations
 
-$15.09 mln
 
Q2 Loss Per Basic Share
 
$2.80
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for NextCure Inc is $17.50, about 233.3% above its August 5 closing price of $5.25

Reuters Recommended Reads
Aug 6 - ALX Oncology Q2 net loss narrows on lower R&D costs
Aug 6 - Prime Medicine Q2 net loss narrows on lower expenses
Aug 5 - Entrada Therapeutics Q2 net loss narrows on lower costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)